A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia.

摘要

The antipsychotic drug-related weight gain often necessitates treatment changes or leads to noncompli-ance in patients with schizophrenia (Allison and Casey, 2001). Moreover, excessive weight gain affects general health such as cardiovascular diseases and diabetes mellitus (David and Daniel, 2001). Current available methods to deal with weight gain are dietary restriction, exercise, cognitive-behavioral approach, and pharmacotherapy, which focus on reversing weight gain already caused by atypical antipsychotic agents. A more ideal approach is to prevent or limit weight gain at the beginning of administration of antipsychotic agents (Kane, 1999). But to date, very few studies have been published on this view (Cavazzoni et al., 2003).